Arvind Limited (BOM:500101)

Marinus Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	-	564.4	573.2	567.9	597.8	271.2
Short-Term Investments	-	-	-	-	-	589.5
Trading Asset Securities	-	8.7	71.3	-	-	-
Cash & Short-Term Investments	573.1	573.1	644.5	567.9	597.8	860.7
Cash Growth	-11.08%	-11.08%	13.49%	-5.00%	-30.55%	-26.35%
Accounts Receivable	-	11,773	10,698	9,659	11,086	10,917
Other Receivables	-	319.9	371.7	537.3	1,929	960.8
Receivables	-	12,105	11,106	10,492	13,412	12,379
Inventory	-	21,377	19,860	16,490	22,084	11,599
Prepaid Expenses	-	384.4	316.1	262.1	177.6	138.6
Other Current Assets	-	3,280	2,798	3,359	4,126	4,069
Total Current Assets	-	37,719	34,724	31,171	40,397	29,046
Property, Plant & Equipment	-	38,398	33,262	33,053	33,151	35,719
Long-Term Investments	-	1,582	1,677	2,220	774.8	750.1
Goodwill	-	78.7	89.5	89.5	89.5	145.9
Other Intangible Assets	-	162	160.6	242.2	348	595.8
Long-Term Deferred Tax Assets	-	668.5	153.4	160.6	80.1	78
Other Long-Term Assets	-	2,379	2,533	2,195	2,198	865.7
Total Assets	-	80,990	72,604	69,136	77,046	67,207
Accounts Payable	-	16,552	13,753	12,376	21,828	14,003
Accrued Expenses	-	2,190	2,034	1,863	1,645	1,491
Short-Term Debt	-	9,822	9,264	7,519	8,028	6,324
Current Portion of Long-Term Debt	-	1,021	1,359	2,740	1,990	2,295
Current Portion of Leases	-	329.2	263.4	211.5	191.8	239.8
Current Income Taxes Payable	-	59.7	11.1	14.2	2.4	0.4
Current Unearned Revenue	-	127.5	128.6	100.3	87.4	81.2
Other Current Liabilities	-	4,976	4,184	3,576	2,589	1,528
Total Current Liabilities	-	35,077	30,997	28,399	36,360	25,963
Long-Term Debt	-	2,923	2,634	3,783	7,577	11,419
Long-Term Leases	-	1,534	962.7	924.6	863.3	952
Long-Term Unearned Revenue	-	1,127	796.1	741	683.9	725.8
Long-Term Deferred Tax Liabilities	-	1,250	681.6	951.7	1,226	96.4
Other Long-Term Liabilities	-	305.7	274.3	253.7	232.8	342.8
Total Liabilities	-	42,276	36,397	35,093	46,983	39,541
Common Stock	-	2,618	2,616	2,615	2,606	2,589
Additional Paid-In Capital	-	5,782	5,744	5,732	5,692	5,630
Retained Earnings	-	29,012	26,649	24,760	20,575	18,256
Comprehensive Income & Other	-	449	417.9	348.9	632.2	717.2
Total Common Equity	37,861	37,861	35,428	33,456	29,505	27,193
Minority Interest	-	852.5	779.5	586.3	557.4	473.3
Shareholders' Equity	38,714	38,714	36,207	34,043	30,063	27,666
Total Liabilities & Equity	-	80,990	72,604	69,136	77,046	67,207
Total Debt	15,629	15,629	14,483	15,178	18,650	21,230
Net Cash (Debt)	-15,056	-15,056	-13,838	-14,610	-18,052	-20,369
Net Cash Per Share	-57.45	-57.46	-52.86	-55.99	-69.21	-78.91
Filing Date Shares Outstanding	262.27	261.82	261.63	261.5	260.59	258.92
Total Common Shares Outstanding	262.27	261.82	261.63	261.5	260.59	258.92
Working Capital	-	2,641	3,727	2,771	4,037	3,084
Book Value Per Share	144.61	144.61	135.41	127.94	113.23	105.02
Tangible Book Value	37,620	37,620	35,177	33,125	29,068	26,451
Tangible Book Value Per Share	143.69	143.69	134.45	126.67	111.55	102.16
Land	-	12,345	11,675	11,765	11,751	13,231
Buildings	-	6,825	6,682	6,412	6,348	6,125
Machinery	-	31,575	29,277	27,665	26,466	25,436
Construction In Progress	-	4,074	1,168	787.2	453.2	779.5
Leasehold Improvements	-	459.7	449.6	448.2	431	452.1

Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.